The acquisition strengthens and broadens IMA's Clinical Research Division, a physician-founded network of integrated clinical research sites specializing in phase II-IV hybrid and fully decentralized trials in multiple therapeutic areas.

DXRG will continue to operate under its existing name. The financial terms of the deal were not disclosed.

NIIMBL spends $4.6M to fund biopharmaceutical projects
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is spending $4.6 million to fund 10 new biopharmaceutical manufacturing...